Literature DB >> 14718245

Statements of ATS, CDC, and IDSA on treatment of tuberculosis.

José A Caminero, Pere de March.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718245     DOI: 10.1164/ajrccm.169.2.952

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

1.  Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Authors:  Nicola M Zetola; Chawangwa Modongo; Patrick K Moonan; Ronald Ncube; Keikantse Matlhagela; Enoch Sepako; Ronald G Collman; Gregory P Bisson
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

2.  Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies.

Authors:  R Prasad
Journal:  Lung India       Date:  2012-04

3.  Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai.

Authors:  Zarir F Udwadia; Gautam Moharil
Journal:  Lung India       Date:  2014-10

Review 4.  Management of MDR-TB: Review of Iran's Experience.

Authors:  Mohammad Reza Masjedi; Payam Tabarsi; Majid Marjani; Parvaneh Baghaei Shiva; Mahshid Nasehi; Mohammad Mehdi Gooya; Parisa Farnia; Ali Akbar Velayati
Journal:  Tanaffos       Date:  2013

5.  Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai.

Authors:  Zarir F Udwadia; Jai Bharat Mullerpattan; Kushal D Shah; Camilla S Rodrigues
Journal:  Lung India       Date:  2016 May-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.